2021-07-25
"... the assay first introduced in February 2020 for detection of SARS-CoV-2 only"
"CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses"
Of itself this would not invalidate the RT-PCT test technique (although there are many who consider it unsuitable, especially at higher amplification cycles), but it does affect the assay used by the test to identify the target molecular sequences to be amplified.
This announcement seems carefully phrased but the implication is clear enough.
